Shares of Solventum Co. (NYSE:SOLV - Get Free Report) have received a consensus recommendation of "Hold" from the eleven ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $68.29.
A number of equities research analysts have recently commented on the company. BTIG Research initiated coverage on Solventum in a research note on Thursday, September 5th. They set a "neutral" rating on the stock. Mizuho initiated coverage on shares of Solventum in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $70.00 target price on the stock. Morgan Stanley increased their target price on shares of Solventum from $60.00 to $73.00 and gave the company an "equal weight" rating in a research report on Monday, November 11th. Wolfe Research assumed coverage on shares of Solventum in a report on Thursday, September 26th. They issued a "peer perform" rating on the stock. Finally, Stifel Nicolaus assumed coverage on Solventum in a report on Tuesday, October 8th. They set a "buy" rating and a $82.00 price objective for the company.
Read Our Latest Stock Report on Solventum
Hedge Funds Weigh In On Solventum
Several hedge funds have recently bought and sold shares of the company. Trian Fund Management L.P. grew its stake in Solventum by 32.9% in the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company's stock worth $496,842,000 after buying an additional 1,765,676 shares in the last quarter. State Street Corp grew its position in Solventum by 3.1% in the third quarter. State Street Corp now owns 6,107,550 shares of the company's stock worth $425,818,000 after acquiring an additional 185,938 shares in the last quarter. Davis Selected Advisers bought a new position in Solventum in the second quarter valued at $273,070,000. Geode Capital Management LLC raised its position in Solventum by 4.0% during the third quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company's stock valued at $232,608,000 after purchasing an additional 128,317 shares in the last quarter. Finally, Nuance Investments LLC bought a new stake in Solventum during the second quarter worth about $115,829,000.
Solventum Price Performance
Shares of SOLV stock traded down $0.29 during trading on Monday, hitting $69.27. The company's stock had a trading volume of 755,499 shares, compared to its average volume of 1,637,012. The business has a fifty day moving average of $70.91 and a 200-day moving average of $63.24. Solventum has a 52 week low of $47.16 and a 52 week high of $96.05. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.
About Solventum
(
Get Free ReportSolventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Further Reading
Before you consider Solventum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.
While Solventum currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
